A Phase 1, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 06 Nov 2017 Planned End Date changed from 14 Feb 2023 to 31 Mar 2023.
- 06 Nov 2017 Planned primary completion date changed from 7 Sep 2021 to 22 Oct 2021.
- 27 Jun 2017 Planned End Date changed from 1 Dec 2019 to 14 Feb 2023.